Global epidemiological surveillance—anchored by successive iterations of the Global Burden of Disease Study—reveals a fundamental transition in the drivers of primary liver cancer, moving away from classical infectious and toxin-mediated causes (hepatitis B virus, aflatoxin) toward metabolic and behavioral etiologies, chiefly metabolic dysfunction-associated steatohepatitis (MASH) and alcohol use. Quantitative frameworks—age-standardized incidence, mortality, and disability-adjusted life-year (DALY) rates, estimated annual percentage change, frontier analysis, and hierarchical cluster analysis—consistently show that while HBV-related liver cancer burden continues to rise in absolute terms in some regions (e.g., Mongolia, parts of Asia-Oceania), the fastest-growing relative increases in incidence, mortality, and DALYs are now attributable to MASH and alcohol-related disease. Notably, the Americas show the steepest percentage growth in MASH-associated liver cancer burden, while Africa and low-sociodemographic-index (SDI) countries bear the highest absolute incidence and death rates, exposing a widening gap between where burden is growing fastest and where it is most severe. This divergence underscores the tension between economic development, healthcare access, and disease-specific risk exposure (high BMI, alcohol, smoking) as key modifiable drivers now rivaling infectious causes.
A second major thread concerns the double-edged clinical relevance of rare hepatic metabolic disorders—porphyrias—as an underrecognized but clinically significant risk pathway for primary liver cancer. Acute intermittent porphyria and related acute porphyrias, driven by defects in heme synthesis and accumulation of neurotoxic porphyrin precursors, are associated with markedly increased liver cancer risk, necessitating dedicated hepatological surveillance. Liver transplantation emerges as a recurring therapeutic nexus: curative for acute porphyria's neuropathic attacks and for the cholestatic liver failure of erythropoietic protoporphyria, yet complicated by comorbidities and not addressing the systemic porphyric defect. This positions hepatologists at the intersection of rare metabolic disease management and cancer surveillance, a niche but growing area of clinical concern paralleling the broader epidemiological narrative.
Methodologically, the field is converging on standardized quantitative tools—EAPC, ASIR, ASMR, DALYs with 95% CI—paired with socioeconomic stratification (SDI) and geographic/demographic disaggregation (sex, age, region) to model both risk-factor-specific burden (alcohol, high BMI, smoking, HBV, aflatoxin) and disparities in improvement potential (frontier analysis identifying countries like Australia with outsized gains relative to development level). This creates an evidence base supporting differentiated public health strategy: infection control and aflatoxin mitigation in historically high-burden regions, alongside metabolic and alcohol-focused policy interventions in rapidly transitioning economies. Collectively, these threads point toward an integrated future model of liver cancer prevention that couples etiology-specific surveillance (viral, metabolic, toxic, and rare genetic) with socioeconomically tailored policy and clinical intervention, including expanded roles for hepatectomy, transplantation, and microbiota-based prevention/therapeutic strategies.